* Indian Patents on Vaccines

Vaccines are vital for healthcare and immunization programme. It is now exactly 200 years since the first vaccine was tested by Edward Jenner. With the advances in vaccinology it is now possible to prevent most infectious diseases. Sophisticated biotechniques have opened the gateway for designing newer and better vaccines. N ewvaccines are aimed to be safe, stable and potent. Vaccines of tomorrow are poised to fulfil all the basic requirements of an ideal vaccine.

This Patent Scan contains information on vaccines published during April 1972-February 1995. Out of the 52 patents published during 1972-95, nearly 44% of the patents cover most of the common diseases and remaining 56% cover cancer, eczema, meningititis and other viral infections. About 46% of the patents are from European countries followed by USA (19%), India (13%) and the remaining 22% from other countries. The main source of information is the Gazette of India, Part III section 2. The report has been prepared from the IMPAT database developed by IMPD, CSIR

Abbreviations used INTCIASS In ternational Patent Classification

AP Applicant KK Kabusjhiki Kaisha

APP NO Application No LAB Laboratory CC Country Code PAT NO Patent No

DEV Development PUB DATE Publication Date

GOvr Government Country Codes

INC Incorporated AU Australia

IND Industry BE Belgium

INDS Industries CA Canada INST Institute CH Switzerland

INT International CU Cuba

• Contributed by Intellectual Property Management Division, CSIR.

92

DDE

DE

ES

FR

GB

HU

IN

PAT NO/CC

APPNO

INT ClASS

APPLICANT

TITLE

]. INTEllEC. PROP. RIGHTS, MARCH 1996

. Germany IT Italy

Germany JP Japan

Spain KO S. Korea

France ME Mexico

United Kingdom NL Netherlands

Hungary SU Russia

India US USA

132083() PUB DATE : 07-10-72

132083 APPDATE :

SCHWEIZ SERRUM UND IMPFINS1ITtrr UND INS1ITlrr ZUR ERFOURSCHUNG DER INFERKTIONSKANKHEITEN

PROCESS FOR PRODUCING ANHYDROUS SMALLPOX VACCINE

Comprises dispersing lyophilised vaccinia virus in low viscosity, volatile silicop..e oil adding highly viscous silicone oil or silicone paste, continuing the dispersing operation followed by removing the low viscosity silicone oil.

PAT NO/CC

APPNO

INTClASS

APPLICANT

TITLE

94209(DE) PUB DATE: 08-12-73

094209 APP DATE : 11-06-64

BEHRINGWERKE AKTIENGESELLSCHAFT

PROCESS FOR THE MANUFACTURE OF A VACCINE AGAINST FOOT-AND-MOUTH DISEASE

A process for the manufacture of a vaccine against foot-and-mouth disease, ensuring also an immunization of pigs, wherein sapinin in a concentration of 0.1 to 3.5% preferably of 0.75% is added to a suspension of FMD-viruses obtained from tissue cultures of claw-foot animals, especially of calfs kidneys, the FMD-viruses are adsorbed to an adsorbing agent preferably buffered aluminium hydroxide, and inactivated in known manner by means of formaldehyde.

PAT NO/CC

APPNO

INTClASS

10 1623(GB) PUB DATE: 29-12-73

101623 APP DATE: 17-09-65

PRDATA

APPLICANT

TITLE

PATENT SCAN

640930G B-00039819

NATIONAL RESEARCH DEV CORP

IMPROVEMENTS RElATING TO THE PRODUCTION OF ANTI­TIPHOID ORANTI-PARATIPHYOID VACCINES

93

A process for the preparation of an anti-typhoid or anti- paratyphoid vaccine which comprises cultivating a stable non- motile strain of Salmonella typhi or Salmonella paratyphi A or B devoid of flagella capable of producing the corresponding TH, AH, or PH antibodies and thereafter processing the culture in any known manner into the form of a vaccine suitable for parenteral administration to humans.

PAT NO/CC

APPNO

INTCI.ASS

PRDATA:

APPLICANT "

TITLE

89487(GB) PUB DATE: 27-07-74

089487 APP DATE 19-8-60

620822 GB 00032349

THE WELLCOME FOUNDATION LTD

A METHOD FOR THE PRODUCTION OF VACCINES

A method for the production of a concentrated foot and mouth disease vaccine, which comprises the step of adding two different hydrophillic organic polymers to an aqueous suspension containing living attenuated foot-and-mouth disease virus particles to form an aqueous two-phase system so as to make the phase in which the virus preferentially collects smaller in volume than the original virus suspension, and then separating the phase preferen­tially containing the virus.

PAT NO/CC

APPNO

INTCI.ASS

APPLICANT

TITLE

10 1 344(CA) PUB DATE : 16-03-74

101344 APP DATE : 28-10·65

CANADIAN PATENTS AND DEV LTD

IMPROVEM,ENTS IN OR RELATING TO THE PRODUCTION OF SOMATIC ANTIGEN VACCINES

In a process for the production of somatic antigen vaccine by the lysis of inactivated pathogenic bacteria, the improvement comprising the step of growing the said bacteria in a culture medium containing excess amino acid utilized in the synthesis of cell structures, in a concentration between 0.1 to 3% w/v, the actual concentration of said acid in said medium exceec;ling that which promotes growth of said bacteria having normal cell walls, but being less than that which substantially inhibits growth of said bacteria, as determined for the particular bacteria present, thereby producing pathogenic bacteria having substan­tially increased susceptibility to lysing.

94

PAT NO/CC

APPNO

INTCLASS

PRDATA

APPLICANT

TITLE

J. INTELLEC. PROP. RIGHTS, MARCH 1996

112602(BE) PUB DATE : 28-09-74

112602 APP DATE : 03-4(}67

661021 GB00047399

RECHERCHE ET INDUSTRIE THERAPEUTIQUES RIT

A METHOD FOR PRODUCING VACCINE AGAINST RUBELLA

A method for producing a vaccine against rubella consisting in passing serially a rubella virus strain at least 15 times on primary rabbit kidney tissue cultures and, with the so obtained attenuated strain preparing a vaccine according to a procedure known to the art.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

124894(IN) PUB DATE: 06-07-74

124894 APP DATE: 17-01-70

RANADESN

AN IMPROVED METHOD OF PREPARING POLLEN VACCINES

A method of preparing pollen vaccine for eczema, characterised in that the said method involves the steps: (i) removing the Parthenium hysterophorus L grass by uprooting its plant; (ii) plucking the flower-heads and separating them from the said grass either manually by hands or by means of forceps; (iii) wrapping the said flower-heads in paper or the like material and drying them in shade at room temperature for a period, say, about 10 days; (iv) the said flower-heads thus dried, are unwrapped from paper and further dried by keeping in an incubator at a temperature varying from 39°C to 40°C, for about 10 days; (v) the dried flower-heads are then weighed and soaked with distilled water, approximately to the proportion of 2.2 cc. of distilled water for 100 mgm. of flower-heads, for a period of about 12 days; (vi) filtering the entire soaked flower-heads, mixed with the said distilled water; (vii) thereafter, to the filtered extract is added again distilled water, for making the percentage, approximately to the proportion of 1 cc. of distilled water for 50 mgm. of extract; and (viii) finally, filtering the said extract of the step (vii) through a seitz filter and ampouling the said finally filtered extract in sterile glass ~poules, to provide 1 cc. of said extract containing 50 mgm. of Parthenium hysterophorus L flower pollen vaccine.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

125476(FR) PUB DATE: 13-07-74

125476 APP DATE: 25-02-70

INSTITUT MERIEUX

TITLE

PATENT SCAN

PROCESS FOR THE PRODUCTION OF A VACCINE AGAINST FOOT-AND-MOUTH DISEASE

95

Process for the production of a vaccine against foot-and-mouth disease which comprises cultivating the virus of foot-and-mouth disease on glossal epithelia in a first culture medium, separating the first culture medium, adding fresh culture medium to the glossal epithelia, containing the cultivation in the second culture medium, separating the second culture medium, repeating, if desired, the addition of fresh culture medium and cultivation of the virus therein one or more times, and finally inactivating by known methods the cultivated virus in the separated culture media to produce the vaccine.

PAT NO/CC

APPNO

INTClASS

APPLICANT

TITLE

130453(US) PUB DATE: 12-10-74

130453 APP DATE : 03-03-71

MERCK AND CO INC

PROCESS FOR PREPARING A VACCINE FOR IMMUNIZATION OF POULTRY AGAINST MAREK'S DISEASE

A process for preparing a live virus cell-associated vaccine active against Marek's disease from live Avian Herpesvirus IV of ATCC No. VR 584, which comprises the steps: (a,) inoculating a monolayer cell culture such as herein described with said Avian Herpesvirus IV; (b) incubating the inoculated cell culture until about 75 per cent of the cells therein are infected by said virus; (c) removing the cells from the resulting incubated culture, separat­ing the cells with trypsin, and replating them on fresh monolayer cell cultures in known mann er such as h erein described; (d) serially passing them through cell cultures of the same type and in the same manner as described above until a useful quantity of viruliferous cells is obtained; and (e) preserving the said useful quantity of cells by dispersing them in the final passage with trypsin, separating the cells from the liquid portion of th e resulting dispersion in known manner such as herein described, and slowly freezing the live virus infected cells for storage.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

136020(IN) PUB DATE: 10-08-74

0566/72 APP DATE : 1&-~72

AGRAWALSC

PROCESS FORTHE PRODUCTION OF CHOLERA lrFORM LYSATE VACCINE

A process for the production of Cholera lrform lysate vaccine for oral and parenteral immuni­sation comprising induction of lrforms of Vibrio cholerate. Ogawa strain and culturing them in an L-form med ium containing penicillin .

96

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

}. INTELLEC. PROP. RIGHTS, MARCH 1996

136187(US) PUB DATE: 12-10-74

0640CAL73 APP DATE 21-03-73

MERCK AND CO INC

PROCESS FOR PREPARING A LNE CELL-fREE VACCINE FOR IMMUNIZATION OF POULTRY AGAINST MAREK'S DISEASE

A process for the preparation of a live cell-free vaccine active against Marek's disease from live Avian Herpes virus IV of ATCC No.VR 584 which comprises the steps: (a) inoculating a monolayer cell culture selected from the group consisting of chick kidney, chicken embryo fibroblast, and duck embryo fibroblast cultures, with said Avian Herpesvirus IV; (b) incubating the inoculated cell culture until about 75 per cent of the cells therein are infected by said virus; (c) removing the cells from the resulting incubated culture, separating the cells with trypsin, and replating them on fresh monolayer cell cultures; (d) serially passing them through cell cultures of the same type and in the same manner as described above until a useful quantity of viruliferous cells is obtained; and (e) preserving the said useful quantity of cells by dispersing the cells in the final passage with trypsin, separating the cells from the liquid portion of the resulting dispersion, disrupting the cells and separating the suspensions of live virus from said cells in known manner such as herein described.

PAT NO/CC

APPNO

INTCLASS

PRDATA

APPLICANT

TITLE

83880(GB) PUB DATE: 12-07-75

083880 APP DATE 27-08-62

A61K023000,C12KOO5000

610908 GB-00032421

THE WELLCOME FOUNDATION LTD

METIIOD OF OBTAINING A SATISFACTORILY STABLE ATTENUATED MEASLES VIRUS VACCINE

A method of producing a satisfactorily stable measles vaccine containing living attenuated measles virus by growing attenuated measles virus in chick embryo tissue culture, which comprises the steps of infecting chick embryo tissue culture with attenuated measles virus, incubating the infected culture at 32°C, harvesting a wet vaccine by collecting the liquid from the culture, and frreeze-drying the vaccine with the addition of sorbitol.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

84788(US) PUB DATE: 16-08-75

084788 APP DATE 25-10-62

A61K023000,C12KOO5000

THE DOW CHEMICAL CO

TITLE

PATENT SCAN

PROCESS FOR PRODUCING ATfENUATED LIVE MEASLES VIRUS VACCINE

97

Process for the production of a measles vaccine of live attenuated measles virus which comprises propagating and growing the Schewarz strain of measles virus, which has been obtained by the adaptation of native measles virus so that it is capable of growing in living non-human cell tissue or in media containing said living non-human cells and by attenuation of the adapted virus by multiple serial passage through a culture medium comprising living non-human animal cells, at a temperature below 35°C, but at a temperature higher than that at which propagation of the virus ceases, in a culture medium which comprises live animal cells, and separating the cell and debris material from the culture medium by conventional means such as decantation, centrifugation or filtration.

PAT NO/CC 86393(G8) PUB DATE : 02-08-75

APPNO 086393 APPDATE 06-02~3

INTCLASS C12KOO5000,C12KOO7000

PRDATA 620209 GB-OOOO5014

APPLICANT NRDC

TITLE PROCESS FOR TIlE PREPARATION OF VACCINE

A process for the preparation of a vaccine which comprises maintaining a viable culture of cells derived from the baby golden hamster kidney fibroblast cell line designated BHK 21 in a nutrient culture medium containing carbon and nitrogen sources and essential vitamins and mineral salts, inoculating the culture with a virus to which the cells are susceptible, cultivating the virus in the culture and recovering a harvest of virus therefrom.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

98521 (G8) PUB DATE: 30-08-75

098521 APP DATE 1~~5

C12KOO5000,A61K023000

THE WEllCOME FOUNDATION LTD

A method for the production of a primary vaccine by inactivating myxoviruses, which com­prises contacting the viruses in an aqueous suspension at a pH between 6 and 8 in the presence of at least about 0.05% w Iv of a non-ionizing hydrophilic surface active agent with a fully or partially chlorinated and fluorinated lower hydrocarbon other than chloroform, which is liquid at room temperature, separating the organic phase and presenting the aqueous phase as a primary vaccine.

PAT NO/CC

APPNO

123886(G8) PUB DATE: 04-10-75

123886 APPDATE : 05-11~9

98

INTClASS

PRDATA

APPUCANT

TITLE

J. INTEllEC. PROP. RIGJITS, MARCH 1996

C12KOO5000,A61K023000

681118 GB-00054717

NRDC

PROCESS FOR THE PRODUCTION OF A VACCINE ACTIVE AGAINST MAREK'S DISEASE

A process for the production of a vaccine active against Marek's disease characterised in that live attenuated Marek's disease virus, obtained by passaging pathogenic Marek's disease virus in avian cells until such time as the virus has acquired a degree of non-pathogenicity suitable for the preparation of a live vaccine, is formulated in a manner known per se as an antigenic component of the vaccine.

PAT NO/CC

APPNO

INTClASS

APPUCANT

TITLE

126597(DE) PUB DATE: 2!>-o1-75

126597 APP DATE : 11-05-70

BAYERAG

METHOD OF POTENTIATING A FOOT-AND-MOUTH DISEASE VACCINE EMPLOYING DIETHYLAMINOETHYLDEXTRAN

A method of potentiating a foot-and-mouth disease (FMD) vaccine for active immunisation which comprises admixing diethylaminoethyldextran (DEAE-D) with the vaccine in an amount of from 5 to 250 mg of DEAE-D per ml of vaccine.

PAT NO/CC

APPNO

INT ClASS

PRDATA

APPLICANT

TITLE

127368(GB) PUB DATE: 13-12-75

127368 APP DATE 02-07-70

A61K023000,C12KOO5000

690703 GB-00033605

THE WELLCOME FOUNDATION LTD

A METHOD FOR THE PREPARATION OF A VACCINE CONTAINING VIRAL ANTIGENS

A method for the preparation of a vaccine containing viral antigens, which comprises culturing a heteroploid human epithelial liver cell line, such as line WRL 68 as hereinbefore defined, which forms individually separated islands or discrete clumps when cultured in a growth medium such as herein described, has a morphology closely rese~bling that of hepatocytes of the human liver and a generation time not more than 24 hours, manifests increased production of glycogen in the presence of 1% glucose in the medium, and is capable of supporting viruses, by maintaining the cells in a nutrient culture medium such as hereinbefore described, incubating the culture at about 37°C, and thereafter cultivating viruses by inoculat-

PAlENTSCAN 99

ing the cell line or its culture with a virus to which the cells are susceptible, and culturing the cell line, as hereinbefore defined, and the viruses so obtained are further processed in a known manner such as herein described to provide a purified or attenuated strain and a live vaccine.

PAT NO/CC

APPNO

INTCIASS

APPLICANT

TITLE

131052(JP) PUB DATE: 20-12·75

131052 APP DATE 20-04-71

A61K023000,C12KOO5000

RES FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIV

PROCESS FOR PREPARING LIVE VIRUS VACCINES

A process for the preparation of a live virus vaccine effective against diseases such as herein described, which comprises employing a quail embryonated egg or a tissue culture of a quail embryo fibroblast for cultivation of the virus, subjecting a virus such as herein described to successive cultivation of a sufficient number of passages to propagate the virus, wherein at least one passage of said successive cultivation is effected in a culture host selected from the group of a -quail embryonated egg or a quail embryo fibroblast, and thereafter isolating the purifying the vaccine formed by standard techniques.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

134229(DE) PUB DATE : 25-01-75

134229 APP DATE : 10-01-72

STICKLH

VACCINE FORMULATION FOR ORAL VACCINATION AGAINST SMALLPOX

A method for the preparation of a vaccine for oral vaccination against smallpox, which comprises triturating a freeze-dried vaccinia vaccine with a dry surface-active preserving agent such as herein described as well as with a dispersing and a swelling agent, so formed vaccine being protected by a layer so that it does not dissolve until it enters the duodenum.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

138121(IN) PUB DATE : 20-12-75

OOllMAS75 APP DATE : 03-02-75

A61 K023000,C 12KOO5000,C 12KOO9000

AGARWALSC

PROCESS FOR THE PRODUCTION OF ADSORBED CHOLERA VACCINE MIXED LYSATE

100 ]. INTEILEC. PROP. RIGlITS, MARCH 1996

A process for the production of absorbed cholera vaccine mixed lysate comprising culturing (1) vibrio cholera ogawa strain in Ir form agar containing penicillin, (2) vibrio cholerae Inaba strain in Irform agar containing penicillin, lysing the cultures separately, mixing the said lysates of Irforms ofV. cholerae Ogawa and Inaba and adding Al (OHh gel to it as an adjuvant.

PAT NO/CC

APPNO

INTClASS

APPUCANT

TITLE

1 1 3235(FR) PUB DATE: 03-01-76

113235 APP DATE: 20-11-67

C07G017000

RHONE POULENC SA

PROCESS FOR THE PREPARATION OF VIRAL SUSPENSIONS AND OF VACCINES FOR COMBATING INFLUENZA

Process for the preparation of monovalent or polyvalent inactivated vital suspensions of human, equine, porcine or fowl influenza viruses or vaccines containing them which comprises cultivating in the allantoic cavity of the embryonated chicken egg one or more strains of one or other of said viruses, separating the allantoic liquid containing the virus by suction, purifying the viral suspension so obtained by centrifugation, and treating a purified suspension of the virus by adding diethyl ether or ethyl acetate and stirring the mixture at a temperature of 0° to 5°C, to inactivate the virus and to maintain the neuraminidase activity of the virus, if desired mixing two or more monovalent inactivated viral suspensions thus obtained to produce a polyvalent inactivated viral suspensions thus obtained with one or more vegetable or mineral oils of hydrophilic natural triglycerides and an emulsifying agent to obtain a vaccine.

PAT NO/CC

APPNO

INTClASS

APPUCANT

TITLE

139166(BE) PUB DATE : 15-05-76

2053CAL73 APP DATE 07-09-73

A61 K023000,C 12 KOOSOOO

RECHERCHE ET IND THERAPEUTIQUES RlT

PROCESS FOR PREPARING AN IMPROVED VACCINE HAVING ENHANCED ANTIGENIC POTENCY

A process for preparing an improved vaccine in which the antigenic potency is enhanced whiich comprises adding thereto as an adjuvant and per dosage unit of vaccine from 1 to 200 mg of an oxidized polysaccharide having at least 50% of the monosaccharide rings open, substantially all the open rings oxidized to be carboxylic acid state and substantially all the C-O-C linkages originally present in the original polysaccharide still intact.

PAT NO/CC

APPNO

INTClASS

139773(ES) PUB DATE: 31-07-76

l007CAL74 APP DATE : 04-05-74

C12KOOSOOO

PATENT SCAN

731109 GB-05219473

ME]IASFC

101

PRDATA

APPLICANT

TITLE PROCESS FOR PREPARING A VACCINE AGAINST CANCER AND OTHER PATHOLOGICAL PROCESSES HAVING SIMIlAR ETILOGY

Process for preparing a vaccine against cancer and other pathological processes having a similar etiology, essentially characterized in that the use is made of bacillus strains or other non-heat resistant and non-sporulated bacteria, whose lysates show, against the serum of patients suffering from neoplasia, that there is a positive relationship with regards to specificity between them, detectable by analytical procedures, using for such strains semi-synthetic culture media comprised of beer yeast extract, mineral vitamin complex monosodium gluta­mate, proline, leucine, arginine, tyrosine, alanine and urea, in adjusted amounts, so that a completely clean and transparent culture media is obtained, including dist illed water to make up one litre, both component parts being handled according to the following operative steps:

A placing 90 cm3 of the culture medium in a Roux bottle and sterilizing by autoclaving at 1.75 atmospheres for half an hour,

B. inoculating it with the Bacillus strain or other strains which have shown a clear relationship with cancerous processes, as indicated by the serum of cancerous patients in analytical tests,

C. placing same in a culture oven at 37-38°C and maintaining at that temperature for a period of otime necessary for each strain, so that in order to isolate the medium, the velum formed should not have started to disintegrate,

D. carefully tilting the Roux bottle to separate the culture medium, the velum of the bacteria albering to the upper part of the bottle,

E. completely removing the culture medium by tilting the bottle and leaving it to drain, once the velum has adhered to the upper part of the latter, as explained,

F. Once the pure material, such as the velum, exclusively composed of bacteria is obtained, effecting its bacteriolysis firstly adding about 30 cm3 of distilled water to the Roux bottle, stirring and adjusting pH of the contests to 5.5-6 and finally adding to each flask about 100 mgs of lysozyme, leaving same in contact for 1 hour,

G. after expiry of one hour, adding further 20 cm3 of distilled water, mixing well, adding 0.23 cm3 of formaldehyde and transferring the contents to a homogenizer for physical disintegra­tion,

H. introducing the homogenized mixture in a bottle or cylinder and adding 200 cm3 of distilled water, leaving same to stand in a refrigerator for 24 to 48 hours, to allow the remainder of the velum to settle at the bottom,

L. decanting, leaving the off-white sediment of the velum only,

]. collecting the decanted liquid which is left in the refrigerator,

102 J. INTEllEC. PROP. RIGHTS, MARCH 1996

K adding NaOH to the sediment and placing same in a B.M. at 45/50°C for one hour, until the residues of the velum which remained from the physical homogenation, disappears,

L. neutralizing the mixture and adding the neutralized alkaline disintegrated to the decanted solution ,

M. adding 5 per 1000 of phenal and filtering through a sterilizing plate, to allow the solubilized protides and nucleoprotides of the bacteria to pass there through so as to obtain a clean sterile liquid ready to be packed as the vaccine or to be used as an antigen against the serum of patient to establish, in view of the various strains, the specificity which exists with some of them.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

141155(DE) PUB DATE: 22-01-77

0986CAL76 APP DATE 08-06-76

A61K023002, C 12KOO5000

BEHRINGWERKE AG

PROCESS FOR PREPARING VIRUS VACCINES

Process for prepar"ing virus vaccines in cell cultures by proliferation of cells in a culture medium and infection of the cells with a virus, which comprises proliferating the viruses in a culture medium which contains 2 to 10%, preferably 2 to 3% of serum, and diluting the latter during the growth of the cells with further amounts of culture medium and carrying out the last dilution prior to the infection of cells, without isolating them, with a serum-free culture medium.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

142477(FR) PUB DATE: 16-07-77

0104CAL76 APP DATE : 19-01-76

B05B007000

JEAN-CLAUDE OBERT

APPARATUS FOR GENERATING AEROSOLS OF SOLID PARTICLES PARTICULARLY INHALABLE VACCINES

An apparatus for generating aerosols of solid particles, particularly inhalable aerosols of vaccines, composed: of a jet milk or micronizer comprising a cylindrical chamber whose two axial ends are closed by two flat side walls perpendicular to the axis of the chamber, one of which has an axial outlet conduit from the aerosol passing there through, into the chamber inlet nozzles for compressed gas open out tangentially-and means for introducing into said chamber a pulverulent product, which means comprise, one or more cavities of revolution about an axis which each communicate with the inside of said chamber via a channel which passes through one of said side walls and one or more syringes each constituted by a doser tube, containing a determined dose of said pulverulent product and of which the front end is open and is engaged axially, in sealed and easily removed manner, in one of said cavities, each syringe comprising a plunger which slides in said tube and means for pushing said plungers.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

PATENT SCAN

149012(US) PUB DATE: 1&-08-81

0358DEL78 APP DATE 11-0&-78

A61K023000,C12K005000

MCCOLLESTER DL

A PROCESS FOR PRODUCING A VACCINE FOR USE IN THE IMMUNOTHERAPY OF NEOPlASTIC DISEASE

103

A process for producing a vaccine for use in the immunotherapy of neoplastic disease, said vaccine being produced by: (a) obtaining an amount of cancerous tissue from the patient to be treated and suspending said tissue in an aqueous solution of between about 100 and 150 millimolar sodium chloride and between about 5 and 15 millimolar sodium EDTA, (b) disag­gregating the tissue into its component cells, (c) suspending the cells in water, (d) subjecting the suspended cells to hydrodynamic turbulence sufficient to disrupt the cells and detach therefrom the cell components possessing cancer-specific antigens, and (e) contacting and admixing the cell components obtained in step (d) with a source of manganous ion to form the vaccine.

PAT NO/CC

APPNO

INT CLASS

APPLICANT

TITLE

150348(CH) PUB DATE : 18-09-82

0895DEL78 APP DATE 12-12-78

A61K023000,CI2KOO5000

SALCO BASEL AG

PROCESS FOR PREPARING HETERO VACCINE

A process for the preparation of a heterovaccine forthe therapeutic treatment of the Tricho­monas syndrome, wherein some or ali of the strains of Lactobacterium acidophilum which have been deposited with the "Centraalbureau voor Schinnelcultures" in Baarn (Netherlands) under reference CBS 465.77, CBS 466.77, CBS 467.77, CBS 468.77. CBS 469.77, CBS 470.77, CBS 471.77 and CBS 472.77 are cultured individually on a liquid nutrient medium under aerobic conditions, at a pH value of 6.1 to 6.8 and at a temperature of 32 to 45°C, after termination of the culturing the biological material formed is separated off and inactivated and the inactivated microorganisms obtained from the individual strains are mixed with one another, in a physi­ologically tolerated solution, in approximately the same number or individually inactivated cultures are mixed with one another in volume amounts which are approximately inversely proportional to the density of the culture (number of microorganisms per ml of culture liquid) determined after termination of the culturing or after inactivation.

PAT NO/CC

APPNO

INT CLASS

150441(SL) PUB DATE: 09-10-82

0254CAL79 APP DATE 1&-03-74

A61K023000,C 12 KOO9000

104

APPLICANT

TITLE

J. INTELLEC. PROP. RIGHTS, MARCH 1996

UNIV EDAKAR

PROCESS FOR PREPARATION OF POLYVALENT VACCINES AGAINST LEPROSY

Process fo r the preparation of polyvalent vaccines against leprosy, characterized in that it comprises-seeding leprous inoculums taken from patients afflicted with lepromatour leprosy, tuberculoid leprosy or other forms of leprosy, in suitable selective media, said leprous inocu­lums being taken from the group which comprises notably leprous sera, bacillary suspensions derived from leproma (untreated by decontaminants) , crushed leprids, filtrates of BAAR cultures lysed on Loewenstein medium, aged BAAR cultures, inocubating said leprous inocu­lums for three weeks to three months at a temperature comprised between 30 and 37°C and at a pH comprised between 5.4 and 8 at the end of which a culture is harvested which is the leprous strains and which includes at first inframicroscopic fo rms in process of development, to which become added, according to the age of the culture, pre-AR cyanophile forms, and acid-fast bacilli-wherein the harvested culture is sub-cultured in a suitable selective nutrient medium, whose composition is selected according to the form or the association of forms that it is desired to obtain, in which it is maintained for 48 h to 6 weeks at the end of which an abundant multiplication of the germs sought is observed, which is manifested in a liquid medium by a multiplication of at least 2 to 3 months of germs or of colony forming units/ml of liquid medium and, in solid medium, by the formation of a thick microbial culture layer-and in that the culture having reached this stage of growth, is stopped by any suitable sterilizing means, such as the action of heat, or chemical sterlizing agents, after which the killed, and possibly freezedried cultures are formed into unit doses for use as vaccines, said killed cultures comprising at least one of the forms of the Hansen bacillus, namely BAAR, cyanophile forms, forms 2, forms ~ or determined mixtures of several or of all these forms.

PAT NO/CC

APP NO

INTCLASS

APPLICANT

TITLE

153031(IN) PUB DATE : 19-0fr84

0141BOM81 APP DATE : 1&'Ofr81

A61K023000

CANCER RES INST

PROCESS FOR PREPARATION OF ANTI-LEPROSY VACCINE

A process for the preparation of anti-leprosy vaccine which comprises treating ICRC bacilli strain C44 with a buffer saline solution of the kind such as herein described, separating by any known means the treated bacilli and subjecting said bacilli to gamma radiation so· as to inactivate any live bacteria while maintaining without alteration the antigenic characteristics of the bacilli.

PAT NO/CC

APPNO

INTClASS

155663(FR) PUB DATE: 23-02-85

0054CAL83 APP DATE: 13-01-83

C12KOO5000

APPLICANT

TITLE

PATENT SCAN 105

INSTITUT MERIEUX (SCIENCE ANONYME) FRANCE

A METHOD OF PREPARING BIVALENT ANTI-APHTEOUS AND ANTI-COLIBACILLARY VACCINE FOR BOVINES AND PORCINES

A method for preparing a bivalent, anti-aphteous and anti- colibacillary vaccine which com­prises mixing, preferably in a same phase, anti-aphteous vaccinating antigens in the form of viral particles or virions or of the aphteous protein. V.P .. threonin, and antigen of fixation K 99 (or K 88 in the case of vaccines to be used with porcines), where the antigens are mixed in the following proportions 107 to lOR D ECP 50 of aphteous virions for an equivalent of 20 to 40 billion bacteria, or 100 to 300 J..lg ofV.P. threonin for 0.3 to 2 mg of antigen K 99 (or K 88).

PAT NO/CC

APPNO

INTCLASS

PRDATA

APPLICANT

TITLE

161001(NL) PUB DATE : 05-09-87

0567CAL86 APP DATE 28-07-86

C12KOO5000

830812 GB-08321789

BIOGEN NV

PROCESS FOR PRODUCING VACCINES AND COMPOSITIONS AGAINST HEPATITIS B VIRAL INFECTIONS

A process for producing a pharmaceutically acceptable composition that is characterised by a component that elicits in a treated patient the formation of B viral c antigens at titer effective to protect the patient for some period of tim e against hepatitis B viral infection or at a titer effective to lessen the severity of a hepatitis B viral infection in that oatient comprising the step of culturing by a method such as herein described a host transformed with and expressing a DNA sequence encoding at least one polypeptide displaying the antigenicity of hepatitis B virus c antigen.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

162809(IT) PUB DATE: 09-07-88

0289MAS86 APP DATE 18-04-86

C07K070010

ENRICERCHE SPA

PROCESS FOR THE PREPARATION OF A PEPTIDE MIXTURE USEFUL FOR THE MAlARIA VACCINE MANUFACTURE

Process for the preparation of a peptide mixture useful to manufacture malaria vaccine as well as diagnostic kits to detect malaria disease, wherein said peptide is defined by the following formula H-(Asn-Ala-Asn-Pro) n-OH (U

wherein Asn is Asparagine: Ala is Alanine; Pro is Proline and n is comprised from 10 to 100, characterized in that :

(a) a tetrapeptide with the Asn terminal amino group protected having the formula X-Asn-Ala­Asn-Pro-OH (II)

106 J. INTEUEC. PROP. RIGHTS, MARCH 1996

wherein X is acidolabile protecting group is synthesized by homogeneous phase condensation, in the presence of a condensation agent,at a temperature from -lOoC to +40°C

(b) the tetrapeptide (lD is activated by reaction with fluorinate or chlorinate phenyl derivatives to obtain the active ester of said tetrapeptide at the terminal carboxyl group of Pro having the formula X-Asn-Als-Asn-Pro-PY (lID

wherein X has the above meaning and Y is the fluorinate or chlorinate phenol derivative radial;

(c) the amino protecting group is removed from said tetrapeptide (lID by acidolysis to produce the peptide

HCl, H-Asn-Ala-Asn-Pro-OY (IV)

(d) the tetrapeptide (IV) is polycondensated in an inert organic solvent, in the presence of an organic basic catalyst, at a temperature from -15°C to +40°C;

(e) the peptide mixture (D having the formula

H-(Asn-Ala-Asn-Pro)n-OH

is recovered by gel chromatography.

The preparation according to this invention are useful for the malaria vaccine manufacture and for the preparation of diagnostic kits for the detection of malarial diseases.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

163229(NL) PUB DATE : 27-08-88

0234CAL85 APP DATE 28-03-85

A61K023000,C12K050000

CENTRAAL DIERGENEESKUNDIG INSTITUT

A PROCESS FOR PREPARING A MAREK'S DISEASE VIRUS CLONE SUITABLE FOR USE IN A VACCINE

A process for preparing a Marek's disease vaccine which comprises subjecting a strain MDV CVI-988 to serial passages in avian cell cultures and to plaque purification, and selecting a clone which shows improved immunogenicity and is essentially non-pathogenic, especially with respect to highly MD-susceptible Rhode Island Red (RIR) chickens and using the selected clone or a derivative thereof for the production of a vaccine by means of common vaccine preparation techniques.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

164864(AU) PUB DATE: 24-06-89

0360CAL86

A61K039000

CSIRO

APP DATE : 12-05-86

TITLE

PATENT SCAN 107

A METIIOD OF PRODUCING A VACCINE EFFECTIVE IN THE IMMUNISATION OF RUMINANTS AGAINST STAPHYLOCOCCAL MASTITIS

A method of producing a vaccine effective in the immunisation of ruminants against intramam­mary challenge by S. Aures and other species of the genus Stephylococcus, which comprises the steps (i) growing a pseudocapsule-producing strain of S. aureus in vitro in a nutrient growth medium which is enhanced by the addition of milk or a milk component thereof; and (ij) subsequently inactivating the bacteria by a conventional method, and optionally aiding thereto one or more of (iii) an adjuvant which promotes the production of IgGz sub-type antibodies, and (iv) a toxoid component comprising toxoided betahemolysin secreted as an exotoxin by S.aureus.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

165945(FR) PUB DATE: 17-02-90

0423CAL87 APP DATE: 27-05-87

A61K039000

PASTEUR VACCINE

A PROCESS FOR THE PREPARATION OF AN ANTIGENIC FRACTION INTENDED TO BE USED AS THE ACTIVE PRINCIPLE IN AN ORAL CHOLERA VACCINE

A process for the preparation of an antigenic fraction intended to be used as the active principle in an oral cholera vaccine characterized in that one prepared inoculums in agitated culture and in rich nutritive medium, from V cholerae strains of the Ogawa or Inaba serotypes, chosen from among the smooth pathogen strains and in that these inoculums are then used to culture the cholera vibro in a medium which is poor in nutritive elements and free of iron, whereby the biosynthesis of surface antigen and the liberation into the culture medium, of a particular antigenic complex of smooth lipo-polysaccharide and of outer membrane proteins is favoured , said complex having a diameter between 20 and 100 nm, a sedimentation speed of 30 S in 5-15% sucrose gradient, and one subjects the supernatant, after elimination of the bacterial cell bodies, to separation by a method such as herein described by which particles of the antigenic complex having a molecular weight above at least around 100,000 are recovered, said particles being optionally subjected to heat treatment in the presence of a dissociating agent such as herein described.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

167221(IN) PUB DATE: 22-09-90

0277CAL86 APP DATE 08-04-86

A61K039000,A61K039018

ANEJARP

108 ]. INTEllEC. PROP. RIGHTS, MARCH 1996

A PROCESS FOR PREPARING A VACCINE AGAINST TIlE ILERIOSIS IN CATILE

A process for preparing a vaccine against the ileriosis in cattle, comprising the steps of culturing peripheral bovine lymphocytes (PBLs) , in vitro in a tissue culture medium at a temperature of 30°C to 40°C, supplementing the medium with one or more antibiotics as herein described, bovine serum 10 to 20% and lrglutamine at 15 to 25 mm concentration, subpassaging PBLcells into new bottles containing culture medium at every 4 to 5 days intervals, a plurality of times, and allowing the cells to grow, spinning down the cells at 900 to 1100 rpm for 4 to 7 minutes at 15°C to 25°C, harvesting the pack of cells obtained by spinning in the tissue culture'medium supplemented with 15 to 25% faetal calf serum and 7 to 12% dimethyl sulphoxide.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

167607(CU) PUB DATE : 24-11-90

0626MAS88

A61K039000

APP DATE : 0&09-88

CENTRO NACIONAL DE BIOPREPARADOS

A METIIOD FOR OBTAINING A VACCINE AGAINST THE DIFFERENT PATIlOGENIC SEROTYPES OF GROUP B NEISSERIA MENINGITIDIS

A method for obtaining a vaccine against the different pathogenic serotypes of group B Neisseria meningitidis comprising the steps of culturing the strain B Neisseria mentingitidis, suspending the strain in an ultrasonic bath in a detergent adding 0.03 - 1% of an enzyme such as lysozime and extracted at a temperature of between 2 - 10°C for a time of between 5 minutes to 5 hours with stirring at 250 to 950 rpm, the extract thus obtained is centrifuged to separate the cell debris, the supernatant obtained is treated with DNase and RNase and centrifuged, the sediment is suspended in 0.1 to 6% detergent such as sodium deoxycholate, Brij-96, Tween 20 and Tween 80, molecular sieving is carried out with the product thus obtained, to the first peak so collected is added high molecular weight antigenic complex in a proportion of 15% + 3 and subjected to ultrasonic treatment, the complex thus obtained is purified by HPLC chromatography; affinity chromatography with monoclonal antibodies, hydrophobicity chro­matography; ionic exchange chromatography or a combination of any of them; to the protein product thus obtained is added capsular polysaccharide in a proportion 1:1 to 1:4 and an adjuvant to proportion of 20 to 100 meg/protein product meg, and sterilized by cobalt 60 ionizing radiations with doses from 5 to 25kGy and a temperature of between 1 to 4°C to obtain the vaccine.

PAT NO/CC

APPNO

INTCLASS

168963(US) PUB DATE : 27-07-91

0756CAL87

A61K039000

APP DATE: 23-09-87

APPLICANT

TITLE

PATENT SCAN

EMORY UN IV

A METHOD OF PRODUCING AN IMPROVED VACCINE

109

A method of prpducing an improved vaccine which comprises suspending a purified conju­gated flagella in a saline medium at a concentration approximately 100 mg/ml.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

169027(US) PUB DATE : 17-08-91

0228CAL89 APP DATE : 21-03-89

C12N015000

BALLIVETM

PROCESS FOR THE PREPARATION OF A VACCINE

Process for the production of a vaccine against a given pathogenic agent characterised in that polynucleotide sequences which are at least partially composed of stochastic synthetic polynu­cleotides are produced simultaneously in a common milieu, the polynucleotide sequences thus obtained are amplified, screened and/or selected to identify clones of the transformed host cells, containing said polynucleotides sequences producing peptides, polypeptides or proteins having at least one epitope similar to and/or mimetic of at least one of the epitopes a pathogenic agent, or to identify amplified genes capable of being expressed as such peptides, polypeptides of proteins, wherein identification of said clones or said genes is effected using antibodies against pathogenic agent, or other shape complements of the latter thus identified clones are grown in a manner to produce this peptide, polypeptide or protein, or the thus identified genes are isolated and translated to produce the said peptide, polypeptide or protein, and the thus obtained peptide, polypeptide or protein is used for the production of a vaccine against the pathogenic agent.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TITLE

169071(FR) PUB DATE : 31-08-91

0104CAL88 APP DATE: 01-02-89

A61K039000

INSTITUT MERIEUX

PROCESS FOR THE LARGE SCALE PRODUCTION OF RABIES VACCINE

A process for the largescale production of vaccine comprising: (a) passing into successive biogenerators a cell stock comprising a VERO cell strain and a usual liquid nutritive culture medium, each of such successive biogenerators being of increasing volume and being provided for one passage, i.e. one cellular multiplication cycle, said liquid nutritive medium having suspended therein microcarriers as support for cell multiplication and present in an amount ranging from 1 to 10 grams per litre of said liquid nutritive medium, each such passage being carried out with stirring at a rate not greater than 40 rpm and for a period of time ranging from

110 J. INTEllEC. PROP. RIGHTS, MARCH 1996

5 to 8 days, the last of said passages being carried out in a biogenerator of volume of at least 150 litres; (b) drawing off said liquid nutritive medium at the end of the final passage and replacing said liquid nutritive medium with a serum-free liquid nutritive medium; (c) inoculat­ing said cell stock in the last passage biogenerator with a conventional virus and allowing [he virus to develop at a temperature between 35° - 37°C at a pH of about 7.4 to 7.8 and at a partial oxygen pressure of about 10.50 per cent while stirring at a rate not greater than 40 rpm; (d) culturing in a conventional manner the said virus for a period of at least 5 days; (e) withdrawing the liquid phase which is a suspension of cultured virus; (t) filtering the withdrawn liquid suspension; (g) ultrafiltering the filtered liquid suspension so as to increase the concentratiDn of virus Df least 12.5 times; (h) inactivating the cDncentrated suspensiDn by treatment with beta-propiolactDne; and (i) cDncentrating in a cDnventional manner again the virus at least 100 times; G) purifying the inactivated suspension by zonal centrifugatiDn or chromatDgraphy to. Dbtain the vaccine.

PAT NO/CC

APPNO

INTCIASS

APPLICANT

TITLE

169072(FR) PUB DATE: 31-08-91

0105CAL89 APP DATE: 01-02-89

A61K039000

INSTITUT MERIEUX

PROCESS FOR THE lARGE SCALE PRODUCTION OF A VACCINE AGAINST POLIOMYELITIS

PrDcess fDr the large scale production of pDliomyelitis vaccine separately entailing, for each type 1,2 or 3 of poliDmyelitis virus used, stages cDnsisting in multiplying a VERO cell strain beginning with {\ cell stock by means of culturing on microcarriers in suspension in a liquid nutritive medium, said microcarriers being balls with an average diameter of about 50 to. 300 microns in the dry state and with a density very slightly greater than 1, made of dextran polymers and bearing on their sUliaces grafted radicals of di-ethyl-amino-ethyl, with the concentration of microcarriers in terms of weight being between 1 «nd 5 grams per liter of said liquid nutritive medium, by successive passages into increasing volumes of bio-generators, each passage being carried out for six to eight days, the last passage being carried out in a biogeneratDr whDse tank holds at least 150 liters, said liquid nutritive medium cDntaining serum, while stirring at a rate nDt greater than 40 rpm, drawing off the liquid nutritive medium at the end of the final passage and replacing it by another liquid medium cDntaining no. serum, inDculating the biDgenerator Df the last passage with virus, allDwing the virus to develDp at a temperature between 35°C and 37°C, a pH in the vicinity Df 7.4 and a partial oxygen pressure in the vicinity Df 10 per cent, while stirring at a rate nDt greater than 40 rpm, withdrawing the liquid suspension after virus cu1ture, filtering the suspensiDn drawn off, cDncentrating the filtered suspension at least 150 times by means Df ultrafiltratiDn, carrying out a gel filtration Df

the cDncentrated suspensiDn, subjecting the suspensiDn Dbtained to. iDn exchange chrDmatDg­raphy, diluting the cDncentrated suspensiDn Dbtained with a serum free medium, inactivating the suspension thus diluted and purified, then mixing the three suspen"iDns Df the respective

PATENT SCAN 111

types 1,2 and 3 and preparing the individual dosages containing type 1,2 and 3 antigen in desired proportions.

PAT NO/CC

APPNO

lNTCLASS

APPLICANT

TITLE

171154(US) PUB DATE : 08-08-92

0058CAL90

A61K039000

APP DATE: 22-01-90

EMORY UNIVERSI1Y

A METIIOD OF PRODUCING AN IMPROVED VACCINE

A method of producing an improved vaccine which comprises suspending in an aqueous medium, purified flagella which has been conjugated to an antigen by a method as herein described, and adding to the suspension so obtained upto 5.0 mg of an adjuvant which is a block copolymer comprising a polymer of hydrophilic polyoxyethylene built on an ethylene diamine initiator and polymer of hydrophilic polyoxypropylene.

PAT NO/CC

APPNO

INTClASS

APPLICANT

TITLE

171239(US) PUB DATE: 22-08-92

0805CAL90 APP DATE: 17-09-90

A61K039000,A61K039029,G 12N015000

CHIRON CORPORATION

METIIOD FOR PREPARING A VACCINE FOR TREATING HCV (HEPATITIS C VIRUS)

A method for preparing a vaccine for treating HCV (Hepatitis C Virus) compnSIng: (a) preparing a polypeptide comprised of an HCV epitode by a method comprising the steps (i) providing in a manner such as herein described a host cell such as herein described trans­formed in manner such as herein described with a recombinant expression system comprised of an open reading frame (ORF) of DNA derived from HCV c DNA such an open reading frame (ORF) of DNA derived from HCV c DNA such as herein described and wherein the ORF is operably linked to a control sequence compatible with the host cell; and (ij) incubating the transformed host cell under conditions which allow expression of the HCV polypeptide; (b) formulating in a manner such as herein described the said polypeptide in pharmacologically effective dose in a pharmaceutically acceptable excipient such as herein described.

PAT NO/CC

APPNO

INTClASS

APPLICANT

171747(CA) PUB DATE : 26-12-92

1033CAL90 APP DATE 14-12-90

C08BOO 1000,A61 K039000

NATIONAL RESEARCH COUNCIL OF CANADA

112

TIlLE

J. INTEllEC. PROP. RIGHTS, MARCH 1996

METHOD OF MAKING CONJUGATE OF POLYSACCHARIDES FOR USE IN PREPARING A VACCINE

A method of making a conjugate of polysaccharides for use in preparing a vaccine against disease caused by N. meningitides or E. coli, which comprises: (a) modifying the N. meningi­tides group, N. polysaccharide or E. coli, K1 capsular polysaccharide by substituting the sialic acid residue N-acetyl groups with C4- Cg acyl groups, by a method known per se; and (b) conjugating by a known method, the modified polysaccharide with an immunologically suitable protein.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TIlLE

172520(CA) PUB DATE : 11-09-93

0317CAL91 APP DATE : 24-04-91

A61K039000,A61 K039012,A61K039029,A61K039245,A61K039155,A61K 0 39135

NORTH AMERICAN VACCINE INC

PROCESS OF PREPARING A NOVEL VACCINE COMPOSITION FO R USE IN RESPECT 0 F VARIO US VIRAL/PATHOGENIC CONDITIONS IN WARM BLOODED ANIMALS

Process of preparing a novel vaccine composition having improved immunogenicity for use in respect of various viral/pathogenic condition in warm blooded animals comprising mixing immunologicably effective amounts of a homogeneous immuno,'{enic polypeptide such as herein described and an adjuvant of the formula I of the accompanying drawings under predetermined sterile conditions, wherein C is a hydrogen atom, an amino acid residue, or a peptide residue; D is a hydrogen atom, or a pharmaceutically acceptable acid such as hydro­chloric, hydrobromic, phosphoric, sulfuric, tartaric, lactic or acetic acid; E is 4-hydroxybenzyl, benzyl, 4-hydroxyphenyl, 4- aminobutyl, isopropy, methyl, hydrogen, or other residue of a naturally occurring amino acid, such as herein described; A is (CH2n), oxygen or Ch20 and B is (CH2n) or oxygen, and R is an alkyl a group containing 12 to 20 carbon atoms, the relative proportion of polypeptide: adjuvant being 1:0.1 to 5000.

PAT NO/CC

APPNO

INTCLASS

APPLICANT

TIlLE

172751(US) PUB DATE: 20-11-93

0488DEL87

A61K039000

SEKURARD

APP DATE: 08-06-87

A METHOD OF PREPARING TOXOID FOR USE IN THE MANUFACTURE OF VACCINES

A method of proparing toxoid for use in the manufacture of vaccines which comprises treating at least partially isolated toxin such as pertussis toxin and like, having a peptide chain with an oxidant selected from conventional oxidants such as hydrogen peroxide, sodium peroxide,

PATENT SCAN 113

N-<:hlor0-4-methyl- benzenesulfonamide sodium salt (chloramine-n, performic acid, diox­aneperoxide, peridic acid, Na-permanganate, sodium hyprochlorite and mixture thereof to chemically inactivate said toxin and produce the corresponding toxoid retaining immunogenic property of said toxin and thereafter recovering in any known manner, the toxoid so produced.

PAT NO/CC

APPNO

INTClASS

APPLICANT

TITLE

172859(KR) PUB DATE: 18-12-93

0606CAL91 APP DATE : 12-08-91

A61K039000

BORYUNG BIOPHARMA CO.LTD

METHOD FOR PREPARING AN ORAL LIVE TYPHOID VACCINE

A method for obtaining oral typhoid vaccine comprising steps: (i) suspending cultivated bacteria out of tile seed bacteria obtained from typhoid strain ty21a as described herein, in BHI medium, such as herein described, in protective medium such as herein described, e.g. composed of 8% lactose, 1% carboxymethyl cellulose, 5% skin milk, 0.2% MgS04, 7H20 and 1% monosodium glutamate, and lyophilizing the suspended bacteria in the ampule, (ii) activating the lyophilized bacteria and inoculating the activated bacteria in :1 medium, such as herein described, e.g. composed of 37g BHL 5g lrlysine, 30g sorbitol, 1.5g KzHPO, 0.5gMgS04 and 1 litre of distilled water with pH adjustment to 7.0, (iii) fermenting the bacteria in fermenter, and fo rmulating the bacteria for oral use; the ferrmenting temperature in fermentor being (i) at 30°C for first 6 hours, (ij) at 25°C fo r second 2 hours, and (iii) at 20°C for last 14 hours.

PAT NO/CC

APP NO

INTClASS

APPLICANT

TITLE

173000(CA) PUB DATE : 22-01-94

0673CAL91 APPDATE 06-09-91

A61 K039039,A61K039040

NORTH AMERICAN VACCINE INC

PROCESS OF PREPARING A NOVEL VACCINE COMPOSITIONS

A process of preparing a vaccine composition comprising mixing by any known method, a bacterial polysaccharide protein conjugate such as herein described, with at least one adjuvant of fo rmula l. as shown in the accompanying drawing to the step of melting said carrier substance, the step of forming the melt into microspheres by technique known per se, the step of freezing the ~aid microspheres, thereby forming solid non-porous micro spheres having a diameter between 5 and 300 urn wherein the kinetics of dissolution of said carriers substance in a mammalian organisms into which said microspheres have been injected is slower than the kinetics of release of said active substance in said organism, and the step of separating said microspheres into elibrated fractions according their diameters bv technique known per se. form a complex, wherein C is selected from the group consisting of hydrogen, an amino acid residue, and a peptide due; D is selected from the group consisting of hydrogen a pharmaceu­tically acceptable acid; E is selected from the group consisting of 4-aminohydroxybenzyl, 4

114 ]. INTEILEC. PROP. RIGlITS, MARCH 1996

hydroxyphenyl, phenyl, 4- aminobutyl, isopropyl methyl, hydrogen and a residue of a naturally occurring amino acid; A is (CH2)n oxygen or j(H20) and B is (CH2) or oxygen wherein n is 0 to 4, with the proviso that A and B are not the same for (CH2) and oxygen; and R is alkyl or 12 to 20 carbon atoms, the amount of said adjuvant being predetermined to an amount effective to amplify the immunogenicity of the resulting polysaccharide protein conjugate.

PAT NO/CC

APPNO

INTClASS

APPLICANT

TITLE

.

173128(1N) PUB DATE: 12-02-94

0605IAS91

A61K039002

APP DATE : 09-08-91

ASfRAL RESEARCH CENTRE

A METHOD OF PREPARING A VACCINE AGAINST THE INFESTATION OF CYSTICERCUS CELLULOSAE

A method of preparing a vaccine against the infestation of cysticercus cellulosae comprising; (a) preparing a polypeptide antigen by a method comprising the steps (i) treating an intact and undamaged cysticerci from infested pork muscle in vitro in serum free cell culture growth medium containing antibiotics and antifungal agents such as herein described; (ii) discarding all the pork proteins that may be associated with the crysterei in the firslt 24 to 60 hours of the maintenance by repeatedly replacing the medium; (iii) subsequently collecting the medium of intervals until the time of evagination; (b) removing any insoluble debris and cell membrane components remaining in the medium by ultracentrifugation or by other known methods and; (c) isolation of the polypeptide by known methods such as the ammonium sulphate precipita­tion; (vi) formulating in a known manner such as herein described the said polypeptide in pharmacologically effective dose known pharmaceutically acceptable adjuvant such as de­scribed.

PAT NO/CC

APPNO

INTCIASS

APPLICANT

TITLE

173644(IN) PUB DATE: 18-06-94

0759MAS91 APP DATE : 0~10-91

A61K039000

ASTRA RESEARCH CENTRE

A PROCESS FOR THE PREPARATION OF A VACCINE AGAINST THE INFESTATION OF INVASIVE PATHOGENS

A process for the preparation of vaccine against the infestation of invasive pathogens including bacteria, unicellular and multicellular organisms, parasites and viruses by a known method such as herein described which comprises (i) separating by a known method a protein of apparent molecular weight of 6.3KDa, 58KDa or 43KDa obtained by inducing virulent patho­genic bacteria such as herein described with congo red as the induction triggering factor and relating the said proteins by lysis; (ii) formulating in a known manner such as herein described the said protein in pharmacologically effective dose in a known pharmaceutically acceptable adjuvant such as herein described.